A vaccine to kill tapeworm

July 13, 2005

A VACCINE for pigs could help save the 50,000 people a year in poor countries killed by a gruesome parasite. Initial trials suggest it is nearly 100 per cent effective.

The vaccine, developed by a team at the University of Melbourne, Australia, targets a tapeworm called Taenia solium. The adult form, caught from eating undercooked pork, grows only inside the human intestine, stealing nutrients from the host.

This can be debilitating. But far worse is what can happen if people swallow any of the microscopic eggs shed in vast numbers in the faeces of those carrying the adult form. The eggs hatch in the intestine and the immature parasites, known as oncospheres, burrow through the gut wall. They then migrate through the body and lodge themselves in muscles, the eyes and the brain, causing a disease called cysticercosis.

Its symptoms vary depending on the location and number of what are called cysticerci. Many people have no serious symptoms, but some go blind, become confused, suffer difficulty with balance or have epileptic seizures. Heavy infections can kill, often as a result of inflammation after the parasites die. The parasite has been virtually eliminated in developed countries, but even in the US there are around 1000 cases each year, mainly among immigrants. In central and South America, Asia and Africa, millions of people have symptoms of the disease.

While humans are the main host for T. solium, pigs are the intermediate host, and an essential step in the tapeworm's life cycle. If a pig eats the eggs then, as in humans, the eggs hatch in the intestine, burrow through the gut wall and travel to muscles, where they form cysticerci. The infection rarely causes symptoms in pigs.

Only cysticerci- not eggs- can develop into the adult form, so if you prevent infection in pigs, you can break the life cycle, says team member Charles Gauci. The Australian group has created a vaccine based on two proteins found on the oncosphere. The vaccine triggers the production of antibodies by the immune system that cause oncospheres to burst.

Small-scale trials, in which eggs isolated from adult tapeworms were fed to up to 30 pigs, have already been conducted in Mexico, Peru, Cameroon and Honduras. The vaccine provided between 99.5 and 100 per cent protection in every trial. The Melbourne researchers, together with collaborators in Lima, Peru, now have plans for larger field trials in which the pigs will be allowed to forage as normal, they reported at a conference on parasitology in Melbourne last week. At the moment, two vaccinations about one month apart provide several months of immunity. The team's aim is to provide lifelong immunity with one or two shots, though they say the vaccine will still be beneficial even it has to be given yearly.

There is no reason why the vaccine would not work in people too. But safety issues make it much more costly to develop a human vaccine, and it should not be necessary, says Gauci. "An effective control programme would involve treating people with existing drugs to remove tapeworm from a population and preventing the reinfection of the human population by vaccinating pigs," he says.
-end-
"This article is posted on this site to give advance access to other authorised media who may wish to quote extracts as part of fair dealing with this copyrighted material. Full attribution is required, and if publishing online a link to www.newscientist.com is also required. The story below is the EXACT text used in New Scientist, therefore advance permission is required before any and every reproduction of each article in full. Please contact celia.thomas@rbi.co.uk. Please note that all material is copyright of Reed Business Information Limited and we reserve the right to take such action as we consider appropriate to protect such copyright."

THIS ARTICLE APPEARS IN NEW SCIENTIST MAGAZINE ISSUE: 16 July 2005

Author: Emma Young

IF REPORTING ON THIS STORY, PLEASE MENTION NEW SCIENTIST AS THE SOURCE AND, IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO: http://www.newscientist.com

New Scientist

Related Vaccine Articles from Brightsurf:

Who should get the COVID-19 vaccine first?
Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution -- called the Fair Priority Model -- which aims to reduce premature deaths and other irreversible health consequences from COVID-19.

Breakthrough with cancer vaccine
Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers.

How to improve the pneumococcus vaccine
Pneumococcus kills 1 million children annually according to the World Health Organization.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Successful MERS vaccine in mice may hold promise for COVID-19 vaccine
In a new study, published April 7 in mBio, researchers from the University of Iowa and the University of Georgia demonstrate that a new vaccine fully protects mice against a lethal dose of MERS, a close cousin of COVID-19.

Coronavirus Vaccine: Where are we and what's next? (video)
You might have heard that COVID-19 vaccine trials are underway in Seattle.

Why isn't there a vaccine for staph?
A study from Washington University School of Medicine in St.

Exposing vaccine hesitant to real-life pain of diseases makes them more pro-vaccine
New research from Brigham Young University professors finds there is a better way to help increase support for vaccinations: Expose people to the pain and suffering caused by vaccine-preventable diseases instead of trying to combat people with vaccine facts.

Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.

On the horizon: An acne vaccine
A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine.

Read More: Vaccine News and Vaccine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.